A PEACE-ful solution to COPD exacerbations?

The Lancet

Volumn 371, Issue 9629, 2008, Pages 1975-1976

  Albert, Paul ^a   Calverley, Peter ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CARBOCISTEINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; PNEUMOCOCCUS VACCINE;

ANTICHOLINERGIC EFFECT; ARTICLE; BIOMASS ENERGY; CHRONIC OBSTRUCTIVE LUNG DISEASE; COST EFFECTIVENESS ANALYSIS; DISEASE EXACERBATION; FORCED EXPIRATORY VOLUME; HEALTH CARE COST; HEALTH STATUS; HUMAN; INFLUENZA VACCINATION; MORTALITY; PRIMARY PREVENTION; PRIMARY PRODUCTION (BIOMASS); PRIORITY JOURNAL; SECONDARY PREVENTION; SECONDARY PRODUCTION (BIOMASS); SMOKING;

EID: 44849084468     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(08)60845-4     Document Type: Note

References (14)

1. Buist A., McBurnie M., Vollmer W., et al., on behalf of the BOLD Collaborative Research Group. International variation in the prevalence of COPD (The BOLD Study): a population-based prevalence study. Lancet 370 (2007) 741-750
2. Niewoehner D., Rice K., Cote C., et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial. Ann Intern Med 143 (2005) 317-326
3. Calverley P., Anderson J., Celli B., et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 356 (2007) 775-789
4. Calverley P., and Rennard S. What have we learned from large drug treatment trials in COPD?. Lancet 370 (2007) 774-785
5. Soler-Cataluna J., Martinez-Garcia M., Roman S.P., Salcedo E., Navarro M., and Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 60 (2005) 925-931
6. Rabe K., Hurd S., Anzueto A., et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 176 (2007) 532-555
7. Poole P., and Black P. Oral mucolytic drugs for exacerbations of chronic obstructive pulmonary disease: systematic review. BMJ 322 (2001) 1271
8. Decramer M., Rutten-van M.M., Dekhuijzen P., et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial. Lancet 365 (2005) 1552-1560
9. Zheng J.-P., Kang J., Huang S.-G., et al. Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomised placebo-controlled study. Lancet 371 (2008) 2013-2018
10. 2 agonists) study group. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 361 (2003) 449-456
11. Calverley P. Minimal clinically important difference: exacerbations of COPD. COPD 2 (2005) 143-148
12. Zhou Y., Wang X., Zeng X., et al. Positive benefits of theophylline in a randomized, double-blind, parallel-group, placebo-controlled study of low-dose, slow-release theophylline in the treatment of COPD for 1 year. Respirology 11 (2006) 603-610
13. Wedzicha J., Calverley P., Seemungal T., Hagan G., Ansari Z., and Stockley R. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 177 (2008) 19-26
14. Zhong N., Wang C., Yao W., et al. Prevalence of chronic obstructive pulmonary disease in China: a large, population-based survey. Am J Respir Crit Care Med 176 (2007) 753-760